0001209191-21-052397.txt : 20210818 0001209191-21-052397.hdr.sgml : 20210818 20210818191111 ACCESSION NUMBER: 0001209191-21-052397 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210817 FILED AS OF DATE: 20210818 DATE AS OF CHANGE: 20210818 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GARCIA PETER S CENTRAL INDEX KEY: 0001188956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39386 FILM NUMBER: 211187909 MAIL ADDRESS: STREET 1: ALX ONCOLOGY HOLDINGS INC. STREET 2: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC CENTRAL INDEX KEY: 0001810182 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850642577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650-466-7125 MAIL ADDRESS: STREET 1: 866 MALCOLM ROAD, SUITE 100 CITY: BURLINGAME STATE: CA ZIP: 94010 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-17 0 0001810182 ALX ONCOLOGY HOLDINGS INC ALXO 0001188956 GARCIA PETER S C/O ALX ONCOLOGY HOLDINGS INC. 866 MALCOLM ROAD, SUITE 100 BURLINGAME CA 94010 0 1 0 0 Chief Financial Officer Common Stock 2021-08-17 4 M 0 10000 4.08 A 19331 D Common Stock 2021-08-17 4 S 0 4687 65.2352 D 14644 D Common Stock 2021-08-17 4 S 0 2368 65.8329 D 12276 D Common Stock 2021-08-17 4 S 0 505 67.1267 D 11771 D Common Stock 2021-08-17 4 S 0 2400 68.3355 D 9371 D Common Stock 2021-08-17 4 S 0 40 68.62 D 9331 D Employee Stock Option (right to buy) 4.08 2021-08-17 4 M 0 10000 0.00 D 2030-03-09 Common Stock 10000 136289 D Employee Stock Option (right to buy) 4.08 2030-03-09 Common Stock 99838 99838 D Includes 203 shares acquired under the Issuer's employee stock purchase plan on June 30, 2021. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 14, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.58 to $65.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.58 to $66.55, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.605 to $67.60, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.615 to $68.61, inclusive. The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vested on January 2, 2021 and 1/36th of the remaining shares vest monthly thereafter. The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vest on March 9, 2021 and 1/36th of the remaining shares vest monthly thereafter. /s/ Peter Garcia 2021-08-18